MyFinsight
Home
Blog
About
Marketable securities
$127,812,140
(1188.03%↑ Y/Y)
Cash and cash
equivalents
$31,206,707
(-59.86%↓ Y/Y)
Prepaid research and
development
$2,346,641
(1589.99%↑ Y/Y)
Prepaid expenses and
other current assets
$933,938
(36.82%↑ Y/Y)
Deferred offering costs
$44,489
(-85.53%↓ Y/Y)
Total current assets
$162,343,915
(82.83%↑ Y/Y)
Prepaid research and
development, noncurrent
$1,000,000
Other assets
$244,697
Total assets
$163,588,612
(84.11%↑ Y/Y)
Total liabilities and
stockholders' equity
$163,588,612
(84.11%↑ Y/Y)
Total stockholders'
equity
$153,328,586
(91.53%↑ Y/Y)
Total liabilities
$10,260,026
(16.60%↑ Y/Y)
Accumulated deficit
-$178,651,871
(-51.38%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$72,754
(-2371.26%↓ Y/Y)
Additional paid-in capital
$331,921,179
(67.64%↑ Y/Y)
Total current
liabilities
$10,260,026
(16.60%↑ Y/Y)
Common stock, 0.001 par
value 500,000,000...
$132,032
(77.19%↑ Y/Y)
Accrued expenses and
other current...
$9,268,306
(194.62%↑ Y/Y)
Accounts payable
$991,720
(-63.32%↓ Y/Y)
Back
Back
Balance Sheet
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)
source: myfinsight.com